Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012 (2012), Article ID 170496, 4 pages
http://dx.doi.org/10.1100/2012/170496
Clinical Study

Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas

1Department of Oncology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark
2Department of Gastrointestinal Surgery C, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark
3Department of Pathology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark
4Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark
5ENETS NET Centre of Excellence, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark
6Department of Surgery C 2122, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark

Received 9 June 2012; Accepted 25 July 2012

Academic Editors: T. Efferth, L. Eisenbach, and V. Gebbia

Copyright © 2012 Ingrid H. Olsen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [27 citations]

The following is the list of published articles that have cited the current article.

  • F.P. Costa, B. Gumz, and B. Pasche, “Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours,” Best Practice & Research Clinical Gastroenterology, vol. 26, no. 6, pp. 843–854, 2012. View at PublisherView at Google Scholar
  • Pavan Mankal, and Eileen O'Reilly, “Sunitinib malate for the treatment of pancreas malignancies – where does it fit?,” Expert Opinion on Pharmacotherapy, vol. 14, no. 6, pp. 783–792, 2013. View at PublisherView at Google Scholar
  • Halfdan Sorbye, Jonathan Strosberg, Eric Baudin, David S. Klimstra, and James C. Yao, “Gastroenteropancreatic High-Grade Neuroendocrine Carcinoma,” Cancer, vol. 120, no. 18, pp. 2814–2823, 2014. View at PublisherView at Google Scholar
  • Dimitrios Karakaxas, Maria Gazouli, Theodoros Liakakos, Anna Vaiopoulou, Dimitra Apessou, Kleo Papaparaskeva, Pavlos Patapis, and Christos Dervenis, “Pancreatic neuroendocrine tumors,” European Journal of Gastroenterology & Hepatology, vol. 26, no. 8, pp. 826–835, 2014. View at PublisherView at Google Scholar
  • Ingrid Holst Olsen, Ulrich Knigge, Birgitte Federspiel, Carsten Palnaes Hansen, Anna Skov, Andreas Kjaer, and Seppo W. Langer, “Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas,” Journal of Cancer, vol. 5, no. 8, pp. 628–632, 2014. View at PublisherView at Google Scholar
  • M. Heetfeld, C. N. Chougnet, I. H. Olsen, A. Rinke, I. Borbath, G. Crespo, J. Barriuso, M. Pavel, D. O'Toole, and T. Walter, “Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms,” Endocrine-Related Cancer, vol. 22, no. 4, pp. 657–664, 2015. View at PublisherView at Google Scholar
  • J. Hadoux, D. Malka, D. Planchard, J. Y. Scoazec, C. Caramella, J. Guigay, V. Boige, S. Leboulleux, P. Burtin, A. Berdelou, Y. Loriot, P. Duvillard, C. N. Chougnet, D. Deandreis, M. Schlumberger, I. Borget, M. Ducreux, and E. Baudin, “Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma,” Endocrine-Related Cancer, vol. 22, no. 3, pp. 289–298, 2015. View at PublisherView at Google Scholar
  • Emma Ilett, Seppo Langer, Ingrid Olsen, Birgitte Federspiel, Andreas Kjær, and Ulrich Knigge, “Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review,” Diagnostics, vol. 5, no. 2, pp. 119–176, 2015. View at PublisherView at Google Scholar
  • Georg Maschmeyer, Lars-Olof Mügge, Dietrich Kämpfe, Ute Kreibich, Stephan Wilhelm, Michael Aßmann, Maik Schwarz, Christoph Kahl, Susanne Köhler, Norbert Grobe, and Dietger Niederwieser, “A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010–2012,” Journal of Cancer Research and Clinical Oncology, 2015. View at PublisherView at Google Scholar
  • Lingani Mbakile-Mahlanza, Lenore Manderson, and Jennie Ponsford, “The experience of traumatic brain injury in Botswana,” Neuropsychological Rehabilitation, pp. 1–23, 2015. View at PublisherView at Google Scholar
  • Anna Koumarianou, Gregory Kaltsas, Matthew H. Kulke, Kjell Oberg, Jonathan R. Strosberg, Francesca Spada, Salvatore Galdy, Massimo Barberis, Caterina Fumagalli, Alfredo Berruti, and Nicola Fazio, “Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects,” Neuroendocrinology, vol. 101, no. 4, pp. 274–288, 2015. View at PublisherView at Google Scholar
  • Anna Pellat, Marie Wislez, Magali Svrcek, Pascal Hammel, Pauline Afchain, and Thierry André, “Prise en charge thérapeutique des tumeurs neuroendocrines peu différenciées pulmonaires et des carcinomes neuroendocrines digestifs,” Bulletin du Cancer, 2016. View at PublisherView at Google Scholar
  • Daniela Mueller, Sebastian Krug, Moushumee Majumder, Anja Rinke, and Thomas Matthias Gress, “Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors,” BMC Cancer, vol. 16, no. 1, 2016. View at PublisherView at Google Scholar
  • Birgitta I. Hiddinga, Patrick Pauwels, Annelies Janssens, and Jan P. van Meerbeeck, “O6-Methylguanine-DNA methyltransferase (MGMT): A drugable target in lung cancer?,” Lung Cancer, 2016. View at PublisherView at Google Scholar
  • J Cros, O Hentic, V Rebours, M Zappa, N Gille, N Theou-Anton, D Vernerey, F Maire, P Lévy, P Bedossa, V Paradis, P Hammel, P Ruszniewski, and A Couvelard, “MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors,” Endocrine-Related Cancer, vol. 23, no. 8, pp. 625–633, 2016. View at PublisherView at Google Scholar
  • Patricia Freis, Catherine Lombard-Bohas, and Thomas Walter, “Management of gastroenteropancreatic neuroendocrine carcinoma in 2016,” Hepato-Gastro and Oncologie Digestive, vol. 23, no. 4, pp. 319–326, 2016. View at PublisherView at Google Scholar
  • Jennifer R. Eads, “Poorly Differentiated Neuroendocrine Tumors,” Hematology/Oncology Clinics of North America, vol. 30, no. 1, pp. 151–162, 2016. View at PublisherView at Google Scholar
  • R. Garcia-Carbonero, H. Sorbye, E. Baudin, E. Raymond, B. Wiedenmann, B. Niederle, E. Sedlackova, C. Toumpanakis, M. Anlauf, J. B. Cwikla, M. Caplin, D. O'Toole, and A. Perren, “ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas,” Neuroendocrinology, vol. 103, no. 2, pp. 186–194, 2016. View at PublisherView at Google Scholar
  • Rocio Garcia-Carbonero, Jie Chen, Wouter De Herder, Marianne Pavel, Anja Rinke, Martyn Caplin, Vera Gorbounova, Barbro Eriksson, Matthew Kulke, Jenny Falkerby, Frederico Costa, Catherine Lombard-Bohas, Juan W. Valle, Nicola Fazio, Juan O'Connor, and Halfdan Sorbye, “ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Chemotherapy,” Neuroendocrinology, vol. 105, no. 3, pp. 281–294, 2017. View at PublisherView at Google Scholar
  • A. Faggiano, F. Lo Calzo, G. Pizza, R. Modica, and A. Colao, “The safety of available treatments options for neuroendocrine tumors,” Expert Opinion on Drug Safety, pp. 1–13, 2017. View at PublisherView at Google Scholar
  • T. Walter, D. Tougeron, E. Baudin, K. Le Malicot, T. Lecomte, D. Malka, O. Hentic, S. Manfredi, I. Bonnet, R. Guimbaud, R. Coriat, C. Lepère, C. Desauw, A. Thirot-Bidault, L. Dahan, G. Roquin, T. Aparicio, J.-L. Legoux, C. Lombard-Bohas, J.-Y. Scoazec, C. Lepage, G. Cadiot, Laetitia Stephanie, Ivan Borbath, Castex, Caroline Petorin, Eric Terrebonne, Karine Bouhier-Leporrier, Etienne Suc, Vincent Hautefeuille, Vincent Bourgeois, Laurent Cany, François Dewaele, Patricia Niccoli, Jean-François Seitz, Cédric Lecaille, Christine Rebischung, Valérie Rossi, Mathieu Baconnier, Olivier Dubreuil, Marc Ferec, Gael Deplanque, Guillaume Geslin, Isabelle Wanicki Caron, Sandrine Lavau Denes, Laurent Bedenne, Catherine Ligeza, Eric Maringe, Anne-Laure Ran-Royo, Joel Guigay, and Philippe Rougier, “Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort,” European Journal of Cancer, vol. 79, pp. 158–165, 2017. View at PublisherView at Google Scholar
  • Renate B. Galleberg, Ulrich Knigge, Eva Tiensuu Janson, Lene Weber Vestermark, Sven-Petter Haugvik, Morten Ladekarl, Seppo W. Langer, Henning Grønbæk, Pia Österlund, Geir Olav Hjortland, Jörg Assmus, Laura Tang, Aurel Perren, and Halfdan Sorbye, “Results after Surgical Treatment of Liver Metastases in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas,” European Journal of Surgical Oncology (EJSO), 2017. View at PublisherView at Google Scholar
  • Yordanova, Ahmadzadehfar, Schmidt-Wolf, Fischer, Kristiansen, Essler, Gonzalez-Carmona, Strassburg, Mayer, Feldmann, and Lingohr, “A Step-by-Step Clinical Approach for the Management of Neuroendocrine Tumours,” Hormone and Metabolic Research, vol. 49, no. 2, pp. 77–85, 2017. View at PublisherView at Google Scholar
  • Anja Rinke, and Thomas M. Gress, “Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers,” Digestion, vol. 95, no. 2, pp. 109–114, 2017. View at PublisherView at Google Scholar
  • Thomas Walter, David Malka, Olivia Hentic, Catherine Lombard-Bohas, Karine Le Malicot, Denis Smith, Aurélie Ferru, Eric Assenat, Guillaume Cadiot, Astrid Lievre, Jean-Emmanuel Kurtz, Laetitia Dahan, Olivier Dubreuil, Vincent Hautefeuille, Céline Lepere, Alice Gangloff, Farid Elhajbi, Romain Coriat, Guillaume Roquin, Nadia Bouarioua, Victoire Granger, Jean-Yves Scoazec, and Côme Lepage, “Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41–BEVANEC randomized phase II study,” Digestive and Liver Disease, 2017. View at PublisherView at Google Scholar
  • Jie Li, Xicheng Wang, Jifang Gong, Jing Gao, Yan Li, Lin Shen, Ming Lu, Zhihao Lu, Zhongwu Li, Yiqiang Liu, Li Yang, Jian Li, Xiaotian Zhang, and Jun Zhou, “Irinotecan plus cisplatin followed by octreotide longacting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study,” Oncotarget, vol. 8, no. 15, pp. 25669–25678, 2017. View at PublisherView at Google Scholar
  • Teresa Starzyñska, Jaroslaw B. Cwikla, Andrzej Deptala, Massiomo Falconi, Wanda Foltyn, Daria Handkiewicz-Junak, Alicja Hubalewska-Dydejczyk, Barbara Jarzab, Roman Junik, Dariusz Kajdaniuk, Grzegorz Kamiñski, Magdalena Londzin-Olesik, Agnieszka Kolasiñska-Cwikla, Aldona Kowalska, Robert Król, Leszek Królicki, Jolanta Kunikowska, Katarzyna Kucnierz, Pawel Lampe, Dariusz Lange, Anna Lewczuk-Myclicka, Andrzej Lewiñski, Agata Baldys-Waligórska, Michal Lipiñski, Bogdan Marek, Anna Nasierowska-Guttmejer, Ewa Nowakowska-Dulawa, Joanna Pilch-Kowalczyk, Piotr Remiszewski, Violetta Rosiek, Marek Ruchala, Lucyna Siemiñska, Anna Sowa-Staszczak, Tomasz Bednarczuk, Katarzyna Steinhof-Radwañska, Janusz Strzelczyk, Krzysztof Sworczak, Anhelli Syrenicz, Andrzej Szawlowski, Marek Szczepkowski, Ewa Wachula, Wojciech Zajêcki, Anna Zemczak, Wojciech Zgliczyñski, Jolanta Blicharz-Dorniak, Beata Kos-Kudla, Marek Bolanowski, Agnieszka Boratyn-Nowicka, Malgorzata Borowska, and Andrzej Cichocki, “Colorectal neuroendocrine neoplasms-management guidelines (recommended by the Polish Network of Neuroendocrine Tumours),” Endokrynologia Polska, vol. 68, no. 2, pp. 250–260, 2017. View at PublisherView at Google Scholar